Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

Women who undergo surgical treatment for endometriosis have lower risk of ovarian cancer

A novel study shows women who undergo surgical treatment for endometriosis have a lower risk of developing ovarian cancer. According to results published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, hormonal treatments for endometriosis did not lower ovarian cancer risk.

11 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

AACR recognizes UT MD Anderson professor for contributions to cancer research

Guillermina "Gigi" Lozano, Ph.D., chair and professor in the Department of Genetics at The University of Texas MD Anderson Cancer Center, is the recipient of the 16th annual Women in Cancer Research Charlotte Friend Memorial Lectureship awarded by The American Association for Cancer Research, recognizing her contributions to the field of cancer research and the advancement of women in science.

10 Apr 2013

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.

10 Apr 2013

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.

10 Apr 2013

Nearly 50% of breast cancer patients at high risk of carrying BRCA mutation do not undergo genetic testing

Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation - based on age, diagnosis, and family history of breast or ovarian cancer - reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.

8 Apr 2013

New two-step immunotherapy approach offers new hope for ovarian cancer patients

As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

Wistar scientists describe mechanics of oncogene-induced senescence

Researchers from The Wistar Institute explain a new molecular mechanism behind the phenomenon of oncogene-induced senescence. By depriving the cell of the ability to make new nucleotides-the building blocks of DNA molecules-cells can suppress cancer development by forcing a damaged cell into a senescent state, where the cell remains alive yet cannot reproduce.

5 Apr 2013

New genetic variants may increase susceptibility to breast, prostate and ovarian cancers

The European Collaborative Oncological Gen-‐Environmental Study (COGS) project, whose main goal is to decipher the complex genetic bases of breast, prostate and ovarian cancers, publishes a total of 12 research articles in several prestigious journals, including Nature Genetics, Nature Communications, The American Journal of Human Genetics and PLOS Genetics.

4 Apr 2013

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

Illumina, Inc. today announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

From Illumina, Inc. 4 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Women who undergo surgical treatment for endometriosis have lower risk of ovarian cancer

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

AACR recognizes UT MD Anderson professor for contributions to cancer research

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Nearly 50% of breast cancer patients at high risk of carrying BRCA mutation do not undergo genetic testing

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

New two-step immunotherapy approach offers new hope for ovarian cancer patients

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Wistar scientists describe mechanics of oncogene-induced senescence

New genetic variants may increase susceptibility to breast, prostate and ovarian cancers

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in